Get the Stockscreener App
1,149.85
0.62%
-7.23
After Hours:
1150.50
0.65
+0.06%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,149.85, with a volume of 2.17M.
It is down -0.62% in the last 24 hours and down -0.88% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,157.08
Open:
$1155
24h Volume:
2.17M
Relative Volume:
0.87
Market Cap:
$1.02T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
41.39
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
-2.71%
1M Performance:
-0.88%
6M Performance:
+20.46%
1Y Performance:
+39.30%
1-Day Range:
$1,139.85
$1,158.72
1-Week Range:
$1,139.85
$1,215.00
52-Week Range:
$783.85
$1,292.65
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,149.85 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
258.66 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.93 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
143.81 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.05 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly stock after-hours at EUR 1,028.40: plus 0.07 percent versus prior close - AD HOC NEWS
‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEO - The Economic Times
How Eli Lilly Just Extended Its Lead in the Weight-Loss Drug Market - Barron's
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal - AOL.com
Eli Lilly's Once-Daily Weight Loss Pill Orforglipron Shows Significant Reduction in Heart Disease Risk - Benzinga
Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says - marketscreener.com
Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Foghorn lays off 40% of staff after Lilly collaboration ends - biospace.com
Analyst recommendations: Alphabet, Amazon, Micron, Tesla, Eli Lilly… - marketscreener.com
BMO reiterates Eli Lilly stock Outperform on TRIUMPH-2 data By Investing.com - Investing.com UK
Eli Lilly presents Foundayo data. Eli Lilly and Company stock falls 1.18 percent - AD HOC NEWS
Why Is Eli Lilly (NYSE:LLY) Suddenly a Must-Watch Healthcare Stocks Stock Today? - Kalkine Media
Eli Lilly's Foundayo Shows Promising Results in Reducing Diabetes and Cardiovascular Risks (LLY) - GuruFocus
Eli Lilly's Foundayo Shows Major Diabetes Risk Reduction; LLY St - GuruFocus
Foghorn stock down as Lilly exits collaboration (FHTX:NASDAQ) - Seeking Alpha
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease - PR Newswire
Eli Lilly stock pre-market at EUR 1,025.00: minus 0.26 percent - AD HOC NEWS
Eli Lilly's Ebglyss Phase 3 Success Highlights Growth Potential for LLY - GuruFocus
Eli Lilly Loses Full Fed. Circ. Bid To Nix Teva's $177M IP Win - Law360
Lilly combo drug cuts weight up to 23% in trial - Briefs Finance
Eli Lilly's Foundayo Shows Cardiovascular Benefits in Phase 3 Tr - GuruFocus
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study - PR Newswire
Experimental Lilly combination drug tops Zepbound in weight-loss trial - reuters.com
Missed Out On The Eli Lilly & Novo Nordisk GLP-1 Boom? These 7 Stocks Could Benefit Next! - Stocks Down Under
Doctors condemn big pharma's move to dispense GLP-1s to your door - ABC News & Headlines – Australian Broadcasting Corporation
Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds - USA Today
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo - Fierce Biotech
Eli Lilly Data Shows Retatrutide Promotes Weight Loss Over Eighty Weeks - Benzinga
Eli Lilly's EloraTZP Shows Promising Weight Loss Results in Mid-Stage Trial (LLY) - GuruFocus
Eli Lilly unveils compelling Phase 2b results for its EloraTZP combination - marketscreener.com
Eli Lilly (LLY) Reports Promising Phase 2b Results for EloraTZP in Obesity and Type 2 Diabetes - GuruFocus
Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial - statnews.com
Eli Lilly (LLY) Reports Promising Phase 2b Trial Results for Elo - GuruFocus
Eloralintide: Eli Lilly's New Obesity Treatment Shows Promising Results - GuruFocus
Eli Lilly stock rises on striking 23% weight loss in drug combo trial - Investing.com
What's Behind Eli Lilly's (NYSE:LLY) Big Moment in Healthcare Stocks Today? - Kalkine Media
Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli - Benzinga
Lilly Drug Combo Spurs Record Weight Loss in Diabetes Study - Bloomberg.com
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes - Eli Lilly
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial - cnbc.com
Eli Lilly's Ebglyss Shows Strong Phase 3b Results for Atopic Der - GuruFocus
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Is Eli Lilly and Co (LLY) a Bargain After 0.0% Drop? GF Value Sa - GuruFocus
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Eli Lilly (LLY) Reports Strong TRIUMPH-2 Trial Results for Retat - GuruFocus
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - The Motley Fool
Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results - yahoo.com
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - reuters.com
Wegovy or Zepbound? Eli Lilly Shows Zepbound Outperforms Wegovy in New Weight Loss Data - yahoo.com
Lilly Says Higher-Dose Zepbound Just Widened Its Lead Over Wegovy - Yahoo Finance
Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis - reuters.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):